Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 901 to 950 of 8215 results

  1. Percutaneous ultrasound-guided microwave ablation for symptomatic benign thyroid nodules (IPG743)

    Evidence-based recommendations on percutaneous ultrasound-guided microwave ablation for symptomatic benign thyroid nodules. This involves using microwaves from a wire inserted into the nodule to heat and destroy it (ablation).

  2. NICE recommends adapted shoes for people with severe osteoarthritis

    People with osteoarthritis who are eligible for knee surgery could be offered specially adapted shoes to help with their painful and stiff knees following a draft recommendation by NICE.

  3. Helping to prevent winter deaths and illnesses associated with cold homes

    A quick guide for home care managers on preventing deaths and illnesses associated with cold homes.

  4. Extracorporeal shockwave therapy for calcific tendinopathy in the shoulder (IPG742)

    Evidence-based recommendations on extracorporeal shockwave therapy for calcific tendinopathy in the shoulder. This involves placing a device on the skin that delivers short pulses of sound into the shoulder. The aim is to reduce pain and improve shoulder function.

  5. Advocacy services for adults with health and social care needs (NG227)

    This guideline covers advocacy for people using health and social care services in all adult settings (including young people under 18 using adult services). It describes how to commission and deliver effective advocacy, as well as identifying who should be offered advocacy (including who is legally entitled to it). It also covers monitoring and improving advocacy services, and training and skills for advocates and practitioners.

  6. NICE final draft guidance adds further treatment option for triple-negative breast cancer

    NICE has today (8 November 2022) published final draft guidance which recommends pembrolizumab as an option for people with a type of breast cancer called triple-negative breast cancer.

  7. Supporting you to plan, prioritise and monitor services

    At NICE, we balance best care with value for money, helping you to improve service quality and achieve the best health outcomes for the communities you serve.

  8. Electroacupuncture: Is electroacupuncture a clinically and cost-effective treatment for any subgroup of people with osteoarthritis?

    Recommendation ID NG226/07 Question Electroacupuncture: Is electroacupuncture a clinically and cost-effective treatment for any subgroup

  9. Exercise: What is the clinical and cost effectiveness of supervised group and individual exercise compared with unsupervised exercise for people with osteoarthritis?

    Recommendation ID NG226/01 Question Exercise: What is the clinical and cost effectiveness of supervised group and individual exercise compared

  10. Topical medicines: What is the clinical and cost effectiveness of topical non-steroidal anti-inflammatory drugs and topical capsaicin for osteoarthritis-affected joints other than the knee?

    Recommendation ID NG226/03 Question Topical medicines: What is the clinical and cost effectiveness of topical non-steroidal anti-inflammatory

  11. Manual therapy: What is the clinical and cost effectiveness of manual therapy for people with osteoarthritis, when used alone and when in combination with therapeutic exercise?

    Recommendation ID NG226/06 Question Manual therapy: What is the clinical and cost effectiveness of manual therapy for people with osteoarthritis

  12. Follow-up strategies: What is the clinical and cost effectiveness of patient-initiated follow-up compared with routine follow-up for people with osteoarthritis?

    Recommendation ID NG226/04 Question Follow-up strategies: What is the clinical and cost effectiveness of patient-initiated follow-up compared

  13. Devices: What is the clinical and cost effectiveness of devices compared with usual care for the management of painful foot and or ankle osteoarthritis?

    Recommendation ID NG226/02 Question Devices: What is the clinical and cost effectiveness of devices compared with usual care for the management

  14. Extracorporeal shockwave therapy: What is the clinical and cost effectiveness of extracorporeal shockwave therapy for managing osteoarthritis?

    Recommendation ID NG226/08 Question Extracorporeal shockwave therapy: What is the clinical and cost effectiveness of extracorporeal shockwave

  15. Footwear: What is the clinical and cost effectiveness of footwear for managing lower limb osteoarthritis?

    Recommendation ID NG226/09 Question Footwear: What is the clinical and cost effectiveness of footwear for managing lower limb osteoarthritis

  16. Intra-articular injections:- What is the clinical and cost effectiveness of intra-articular corticosteroids for managing osteoarthritis-affected joints other than the knee? - What is the clinical and cost effectiveness of intra-articular stem cells for managing osteoarthritis?

    Recommendation ID NG226/11 Question Intra-articular injections:- What is the clinical and cost effectiveness of intra-articular corticosteroids

  17. NICE conditionally recommends digital cognitive behaviour therapies for use in the NHS to help children and young people with symptoms of mild to moderate anxiety

    Draft guidance released for consultation today (Friday 4th Nov) states the technologies can be used with support from a mental health professional, while further evidence is generated to check if the benefits they offer are realised in practice.

  18. Towards a new partnership – NICE and the voluntary and community sector

    Victoria Thomas gives details of NICE’s new voluntary and community sector forum, which brings together a range of organisations, including health and care sector charities and not for profit groups, and gives them an opportunity to share their views and help shape NICE’s work in the future

  19. Quality improvement resource for adult social care

    NICE quality improvement resource (QIR) for adult social care

  20. Partnering with us for research - timescales and process

    Whether you are a researcher, funder, charity or policy organisation, you can partner with us for methodological research. As one of the leading...

  21. Slow-release potassium bicarbonate–potassium citrate for treating distal renal tubular acidosis (terminated appraisal) (TA838)

    NICE is unable to make a recommendation on slow-release potassium bicarbonate–potassium citrate (Sibnayal) for treating distal renal tubular acidosis in people 1 year and over. This is because Advicenne withdrew its evidence submission. We will review this decision if the company decides to make a submission.

    Sections for TA838

  22. How we develop NICE guidelines

    The guidance development timeline

  23. Digital technologies for the detection of melanoma (MIB311)

    NICE has developed a medtech innovation briefing (MIB) on digital technologies for the detection of melanoma .

  24. Ventripoint Medical System Plus for measuring heart volume and function (MIB310)

    February 2023: The medtech innovation briefing on Ventripoint Medical System Plus for measuring heart volume and function has been withdrawn as the company have withdrawn from the process.

  25. Commentary - lung cancer

    Professor Michael Peake September 2019 In England the average 5-year survival rate for people diagnosed with lung cancer between 1991 and 1993 was 5%

  26. Making a positive impact

    How people can have an impact on NICE guidance

  27. Oxford University Press

    Provider name: Oxford University Press Lot details Lot 1 - Electronic Journals, Electronic Books, Databases Provider helpdesk

  28. Prevention of lung cancer

    The section of the NICEimpact lung cancer report looking at how lung cancer can be prevented.

  29. Recognition of lung cancer

    The section of the NICE impact lung cancer report looking at how lung cancer is detected.

  30. Diagnosis and staging

    The section of the NICE impact lung cancer report looking at the diagnosis and staging process of lung cancer care.

  31. Treatment for lung cancer

    The section of the NICE impact lung cancer report looking at how the disease is treated.

  32. Lung cancer patient experience

    The section of the NICE impact lung cancer report looking at how patients are treated during their care.

  33. Maternity and mental health

    Part of NICEimpact maternity and neonatal care Previous: Updates from our last maternity report Next: Specialist care of newborns

  34. Specialist care of newborns

    Part of NICEimpact maternity and neonatal care Previous: Maternity and mental health Next: Spotlight on valproate prescribing

  35. Commentary - maternity and neonatal care

    Part of NICEimpact maternity and neonatal care Previous: Spotlight on valproate prescribing Dr Kathryn Gutteridge, President of

  36. Spotlight on valproate prescribing

    Part of NICEimpact maternity and neonatal care Previous: Specialist care of newborns Next: Commentary Babies exposed to

  37. What is NICE doing next?

    Throughout this report we have highlighted examples showing how uptake of our guidance has contributed to improvements in arthritis care. Improvements

  38. Managing long-term conditions in the community

    NICE's impact on managing long-term conditions in children in the community

  39. The learning disability health check programme

    NICE recommends that all children, young people and adults with a learning disability should be offered an annual physical health check

  40. Spotlight on innovative medicines for childhood conditions

    NICE's impact on innovative medicines for childhood conditions

  41. Commentary - children and young people's healthcare

    Commentary by Professor Russell Viner from the Royal College of Paediatrics and Child Health

  42. Prevent or delay the onset of dementia

    NICE's impact on preventing or delaying the onset of dementia

  43. Referral, diagnosis and care planning

    NICE's impact on dementia referral, diagnosis and care planning

  44. Hospital care

    NICE's impact on hospital stays, delays in leaving hospital and independent living